Celltrion’s Remsima SC launches in Netherlands - (The Korea Herald via NewsPoints Desk)

  • Celltrion announced that subcutaneous rheumatoid arthritis treatment Remsima SC, a biosimilar referencing infliximab, launched in the Netherlands, reported The Korea Herald.

  • The company said it inked a partnership with the biggest Dutch private health insurance company CZ, who will return all Remsima SC costs for patients.

  • Aside from the Netherlands, Remsima SC is also distributed in Europe in both Germany and the UK.

To read more NewsPoints articles, click here.

Reference Articles